Please login to the form below

Not currently logged in

Dr James Mond appointed chief medical and scientific officer of ADMA Biologics

Will lead development of RI-001 for primary immunodeficiency disease

US biotech ADMA Biologics has appointed Dr James Mond as its chief medical and scientific officer while the company looks to initiative a phase III study investigating its lead drug candidate for use in the treatment of primary immunodeficiency disease (PIDD).

Dr Mond will be responsible for strategy and advancing all the ADMA's research programme, including the development of RI-001 - a plasma-derived intravenous immune globulin that contains a wide array of antibodies that are obtained from different B-cell resources.

“Dr Mond brings an extensive record of academic and industry clinical and regulatory experience to ADMA, which will be invaluable as we initiate our upcoming phase III study,” said Adam Grossman, president and CEO of ADMA.

Before joining ADMA, Dr Mond was most recently exectuvie VP and chief scientific officer of Biosynexus where he directed all of the preclinical and clinical trial activities.

Previously, he worked as a consultant to Virion Systems, where he oversaw the development of a vaccine technology that the company licensed to GlaxoSmithKline (GSK).

These vaccines have been commercialized to prevent pneumococcal infections and meningococcal infections in children.

25th July 2012


Featured jobs

Subscribe to our email news alerts


Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...